Allianz Asset Management GmbH Buys Shares of 6,200 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Key Points

• Allianz Asset Management GmbH acquired 6,200 shares of ANI Pharmaceuticals, valued at approximately $415,000, in the first quarter, reflecting growing institutional interest in the company.
• Several hedge funds increased their positions in ANI Pharmaceuticals, with Principal Financial Group raising its stake by 68.3%, now owning 157,798 shares valued at over $10 million.
• ANI Pharmaceuticals reported better-than-expected earnings for the last quarter, with an EPS of $1.70 compared to the consensus estimate of $1.37, showcasing a significant year-over-year revenue growth of 43.4%.

Allianz Asset Management GmbH bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,200 shares of the specialty pharmaceutical company's stock, valued at approximately $415,000.

Several other large investors have also recently bought and sold shares of the company. Millennium Management LLC grew its position in ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after purchasing an additional 473,097 shares in the last quarter. Dimensional Fund Advisors LP increased its position in ANI Pharmaceuticals by 4.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after acquiring an additional 30,420 shares during the period. Deep Track Capital LP increased its position in ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock worth $35,879,000 after acquiring an additional 144,214 shares during the period. Geode Capital Management LLC raised its position in shares of ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock valued at $23,720,000 after buying an additional 3,774 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of ANI Pharmaceuticals by 14.6% in the 4th quarter. Ameriprise Financial Inc. now owns 271,805 shares of the specialty pharmaceutical company's stock valued at $15,025,000 after buying an additional 34,586 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock traded up $2.67 on Wednesday, reaching $68.54. The stock had a trading volume of 274,529 shares, compared to its average volume of 320,101. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $77.00. The company has a market cap of $1.48 billion, a P/E ratio of -54.06 and a beta of 0.61. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. The business's 50 day moving average is $64.30 and its two-hundred day moving average is $63.55.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. ANI Pharmaceuticals's quarterly revenue was up 43.4% on a year-over-year basis. During the same period last year, the firm posted $0.82 earnings per share. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. HC Wainwright assumed coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 10th. They issued a "buy" rating and a $84.00 target price for the company. Finally, Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $78.88.

Insider Buying and Selling

In other news, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the sale, the insider owned 107,317 shares in the company, valued at approximately $6,487,312.65. The trade was a 3.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Ori Gutwerg sold 881 shares of the company's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the completion of the transaction, the senior vice president owned 89,897 shares in the company, valued at approximately $5,400,112.79. The trade was a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,681 shares of company stock valued at $345,222 over the last three months. 12.70% of the stock is owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.